S. Rasoul
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
S. Rasoul has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Arnoud W J Van 'T Hof
Isala Klinieken, Dept. of Cardiology, Zwolle, Netherlands
2 shared publications A. Elvan
Isala Klinieken, Dept. of Cardiology, Zwolle, Netherlands
1 shared publicationA. R. Ramdat Misier
Isala Klinieken, Dept. of Cardiology, Zwolle, Netherlands
1 shared publicationA. T. M. Gosselink
Isala Klinieken, Dept. of Cardiology, Zwolle, Netherlands
1 shared publicationF. Demirel
Isala Klinieken, Dept. of Cardiology, Zwolle, Netherlands
1 shared publication- Felix Zijlstra
Ziekenhuis De Weezenlanden, afd. Cardiologie, Zwolle
1 shared publication
Latest Publications
- Open Access
- 13 March 2015
- Published by Springer Nature in Netherlands Heart Journal
- Vol. 23 (4) , 224-231
Multivessel revascularisation versus infarct-related artery only revascularisation during the index primary PCI in STEMI patients with multivessel disease: a meta-analysis
There are controversial data regarding infarct-related artery only (IRA-PCI) revascularisation versus multivessel revascularisation (MV-PCI) in ST-elevation myocardial infarction (STEMI) patients with multivessel disease undergoing primary percutaneous coronary intervention (PCI). We performed a meta-analysis comparing outcome in same stage MV-PCI versus IRA-PCI in STEMI patients with multivessel disease.
- 13 March 2015
- Published by Springer Nature in Netherlands Heart Journal
- Vol. 23 (4) , 224-231
Open AccessMultivessel revascularisation versus infarct-related artery only revascularisation during the index primary PCI in STEMI patients with multivessel disease: a meta-analysis
There are controversial data regarding infarct-related artery only (IRA-PCI) revascularisation versus multivessel revascularisation (MV-PCI) in ST-elevation myocardial infarction (STEMI) patients with multivessel disease undergoing primary percutaneous coronary intervention (PCI). We performed a meta-analysis comparing outcome in same stage MV-PCI versus IRA-PCI in STEMI patients with multivessel disease.
- 1 August 2013
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 34 (suppl 1) , P4932
Impact of out-of-hospital cardiac arrest on outcome in STEMI patients treated with primary PCI
Purpose: Pre-hospital ventricular arrhythmia is common in the acute phase of ST-elevation myocardial infarction (STEMI). We assessed the prognostic impact of out of hospital cardiac arrest (OHCA) in a non-selected STEMI patient population treated with primary percutaneous coronary intervention (PCI). Methods: Registry database of all individual STEMI patients admitted to our hospital during 2005-2010. Patients with OHCA were identified from the register, and their medical records were reviewed. Results: During the study period 4653 patients were admitted with STEMI. Information regarding OHCA was available in 4640 patients (99.7%). A total of 326 patients (7.0%) had OHCA. Patients with OHCA were younger (60.3±11.8 vs. 64.1±12.9, pConclusion: In a large non-selected STEMI patient population treated with primary PCI, OHCA was associated with higher in-hospital mortality but did not affect the long-term prognosis for those discharged alive.
- 1 August 2013
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 34 (suppl 1) , P4932
Impact of out-of-hospital cardiac arrest on outcome in STEMI patients treated with primary PCI
Purpose: Pre-hospital ventricular arrhythmia is common in the acute phase of ST-elevation myocardial infarction (STEMI). We assessed the prognostic impact of out of hospital cardiac arrest (OHCA) in a non-selected STEMI patient population treated with primary percutaneous coronary intervention (PCI). Methods: Registry database of all individual STEMI patients admitted to our hospital during 2005-2010. Patients with OHCA were identified from the register, and their medical records were reviewed. Results: During the study period 4653 patients were admitted with STEMI. Information regarding OHCA was available in 4640 patients (99.7%). A total of 326 patients (7.0%) had OHCA. Patients with OHCA were younger (60.3±11.8 vs. 64.1±12.9, pConclusion: In a large non-selected STEMI patient population treated with primary PCI, OHCA was associated with higher in-hospital mortality but did not affect the long-term prognosis for those discharged alive.
- 1 March 2007
- Vol. 65 (3) , 95-100
Glucose dysregulation in nondiabetic patients with ST-elevation myocardial infarction: acute and chronic glucose dysregulation in STEMI.
Admission hyperglycaemia is associated with an increased risk of mortality after myocardial infarction. Whether long-term glucose dysregulation (assessed by HbA1c) is more important than acute hyperglycaemia is unknown. We evaluated the prognostic value of admission glucose and HbA1c levels in nondiabetic patients with ST-segment elevation acute myocardial infarction (STEMI). In 504 unselected, consecutive patients with STEMI, glucose and HbA1c levels were measured on admission. Glucose was categorised as or= 11.1 mmol/l (n=82). HbA1c levels were categorised as or=6.0% (n=88). Mean follow-up was 1.6+/-0.6 years. Patients with hyperglycaemia on admission were comparable with those with normoglycaemia. However,patients with HbA1c >or=6.0%, as compared with those with HbA1c or=11.1 mmol/l) was 4% and 19% (por=6%) was 5% and 12% (p=0.03). After multivariable analyses, admission glucose (OR 4.91,95% CI 2.03 to 11.9, p< 0.001) but not HbA1c (OR 1.33, 95%CI 0.48 to 3.71, p=0.58) was significantly associated with 30-day mortality. Among 30-day survivors, neither admission glucose nor HbA1c were predictors of long-term mortality. Elevated admission glucose is an important predictor of 30-day outcome after STEMI, while prior long-term glucose dysregulation is a covariate of other high-risk clinical characteristics. Among 30-day survivors, neither admission blood glucose nor HbA1c were predictors of long-term outcome.
- 1 March 2007
- Vol. 65 (3) , 95-100
Glucose dysregulation in nondiabetic patients with ST-elevation myocardial infarction: acute and chronic glucose dysregulation in STEMI.
Admission hyperglycaemia is associated with an increased risk of mortality after myocardial infarction. Whether long-term glucose dysregulation (assessed by HbA1c) is more important than acute hyperglycaemia is unknown. We evaluated the prognostic value of admission glucose and HbA1c levels in nondiabetic patients with ST-segment elevation acute myocardial infarction (STEMI). In 504 unselected, consecutive patients with STEMI, glucose and HbA1c levels were measured on admission. Glucose was categorised as or= 11.1 mmol/l (n=82). HbA1c levels were categorised as or=6.0% (n=88). Mean follow-up was 1.6+/-0.6 years. Patients with hyperglycaemia on admission were comparable with those with normoglycaemia. However,patients with HbA1c >or=6.0%, as compared with those with HbA1c or=11.1 mmol/l) was 4% and 19% (por=6%) was 5% and 12% (p=0.03). After multivariable analyses, admission glucose (OR 4.91,95% CI 2.03 to 11.9, p< 0.001) but not HbA1c (OR 1.33, 95%CI 0.48 to 3.71, p=0.58) was significantly associated with 30-day mortality. Among 30-day survivors, neither admission glucose nor HbA1c were predictors of long-term mortality. Elevated admission glucose is an important predictor of 30-day outcome after STEMI, while prior long-term glucose dysregulation is a covariate of other high-risk clinical characteristics. Among 30-day survivors, neither admission blood glucose nor HbA1c were predictors of long-term outcome.